COST-EFFECTIVENESS OF THE PNEUMOCOCCAL CONJUGATE VACCINE 10 VERSUS 13 ON PNEUMOCOCCAL DISEASE IN CHILDREN IN SWEDEN

被引：0
|
作者：
Peeters, E. [1 ]
Marijam, A. [2 ]
Chevalier, P. [1 ]
Ene, J. [3 ]
Folkesson, J. [3 ]
Izurieta, P. [2 ]
Joost, S. [4 ]
Urbonas, G. [5 ]
Adbelghany, M. [6 ]
机构：
[1] IQVIA, Zaventem, Belgium
[2] GSK, Wavre, Belgium
[3] IQVIA, Solna, Sweden
[4] GSK, Amersfoort, UT, Netherlands
[5] GSK, Warsaw, Poland
[6] GSK, Cairo, Egypt
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE166
引用
收藏
页码：S85 / S85
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
    Jaime E Ordóñez
    John J Orozco
    BMC Infectious Diseases, 14
  • [42] Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
    Ordonez, Jaime E.
    Orozco, John J.
    BMC INFECTIOUS DISEASES, 2014, 14
  • [43] Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
    Sara Tomczyk
    Fernanda C. Lessa
    Jacqueline Sánchez
    Chabela Peña
    Josefina Fernández
    M. Gloria Carvalho
    Fabiana Pimenta
    Doraliza Cedano
    Cynthia G. Whitney
    Jennifer R. Verani
    Hilma Coradin
    Zacarías Garib
    Lucia Helena De Oliveira
    Jesús Feris-Iglesias
    BMC Infectious Diseases, 18
  • [44] The impact of indirect (Herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine
    Isaacman, Daniel J.
    Strutton, David R.
    Kalpas, Edward A.
    Horowicz-Mehler, Nathalie
    Stern, Lee S.
    Casciano, Roman
    Ciuryla, Vincent
    CLINICAL THERAPEUTICS, 2008, 30 (02) : 341 - 357
  • [45] Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China
    Mo, Xiuting
    Tobe, Ruoyan Gai
    Liu, Xiaoyan
    Mori, Rintaro
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (11) : E353 - E361
  • [46] COST-EFFECTIVENESS OF 2+1 DOSING OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE COMPARED WITH 2+1 DOSING OF 10-VALENT CONJUGATE VACCINE IN PREVENTING PNEUMOCOCCAL DISEASE IN CANADA
    Earnshaw, S.
    McDade, C.
    Zanotti, G.
    Farkouh, R. A.
    Strutton, D.
    VALUE IN HEALTH, 2011, 14 (07) : A275 - A275
  • [47] Comment on: “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”
    Raymond A. Farkouh
    Cassandra Hall-Murray
    Rogier M. Klok
    Betsy Hilton
    Raul E. Isturiz
    Infectious Diseases and Therapy, 2015, 4 (2) : 227 - 233
  • [48] COST-EFFECTIVENESS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN KAZAKHSTAN
    Bektur, C.
    Nurgozhin, T.
    VALUE IN HEALTH, 2015, 18 (03) : A106 - A106
  • [49] Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
    Sundaram, Neisha
    Chen, Cynthia
    Yoong, Joanne
    Luvsan, Munkh-Erdene
    Fox, Kimberley
    Sarankhuu, Amarzaya
    La Vincente, Sophie
    Jit, Mark
    VACCINE, 2017, 35 (07) : 1055 - 1063
  • [50] Comment on: "Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children''
    Farkouh, Raymond A.
    Hall-Murray, Cassandra
    Klok, Rogier M.
    Hilton, Betsy
    Isturiz, Raul E.
    INFECTIOUS DISEASES AND THERAPY, 2015, 4 (02) : 227 - 233
12345